Abarceo: restoring beta cell function

Abarceo Pharma AB has identified VDAC1 as a key target in Type II diabetes, and is developing antibodies and small molecule inhibitors against the target as durable and disease-modifying treatments.

Standard first-line therapy for Type II diabetes is metformin, which works mainly by suppressing glucose production in the liver and is dosed once daily. The drug’s MOA is not fully understood but it likely acts on multiple targets, leading to side effects and poor patient compliance...